MedPath

Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day).Twelve-week treatment plus double-blind extension for 12 weeks.

Phase 1
Conditions
Major Depressive Disorder
MedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depression
Registration Number
EUCTR2006-006540-54-FR
Lead Sponsor
Institut de Recherches Internationales Servier
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Outpatients between 18 (or minimum legal age) and 70 years of age (included), male or female, fulfilling DSM-IV criteria for Major Depressive Disorder
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

All types of depression other than Major Depressive Disorder
Severe or uncontrolled organic disease, likely to interfere with the conduct of the study
Women of childbearing potential without effective contraception (oral contraceptive pill, intra-uterine contraceptive device, contraceptive implant or condom) as well as pregnant or breastfeeding women

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To show that patients treated with agomelatine have an earlier improvement of subjective sleep than patients treated with escitalopram;Secondary Objective: To study the effects of agomelatine and escitalopram on depression, other sleep patterns, daytime sleepiness, quality of life and to provide additional safety and acceptability data ;Primary end point(s): Global satisfaction on sleep score expressed in terms of change from baseline
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath